DE60230029D1 - Immunisierungstherapie zur behandlung von atherosklerose - Google Patents

Immunisierungstherapie zur behandlung von atherosklerose

Info

Publication number
DE60230029D1
DE60230029D1 DE60230029T DE60230029T DE60230029D1 DE 60230029 D1 DE60230029 D1 DE 60230029D1 DE 60230029 T DE60230029 T DE 60230029T DE 60230029 T DE60230029 T DE 60230029T DE 60230029 D1 DE60230029 D1 DE 60230029D1
Authority
DE
Germany
Prior art keywords
treatment
atherosclerosis
immunization therapy
cardiovascular diseases
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60230029T
Other languages
English (en)
Inventor
Jan Nilsson
Prediman K Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forskarpatent I SYD AB
Cedars Sinai Medical Center
Original Assignee
Forskarpatent I SYD AB
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101232A external-priority patent/SE0101232D0/xx
Application filed by Forskarpatent I SYD AB, Cedars Sinai Medical Center filed Critical Forskarpatent I SYD AB
Application granted granted Critical
Publication of DE60230029D1 publication Critical patent/DE60230029D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60230029T 2001-04-05 2002-04-05 Immunisierungstherapie zur behandlung von atherosklerose Expired - Lifetime DE60230029D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101232A SE0101232D0 (sv) 2001-04-05 2001-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density liprotein
SE0103754A SE0103754L (sv) 2001-04-05 2001-11-09 Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
PCT/SE2002/000679 WO2002080954A1 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Publications (1)

Publication Number Publication Date
DE60230029D1 true DE60230029D1 (de) 2009-01-08

Family

ID=26655437

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60230029T Expired - Lifetime DE60230029D1 (de) 2001-04-05 2002-04-05 Immunisierungstherapie zur behandlung von atherosklerose

Country Status (18)

Country Link
EP (42) EP2289924A1 (de)
JP (6) JP2004529143A (de)
CN (4) CN1505525B (de)
AT (2) ATE510851T1 (de)
AU (1) AU2002246484B8 (de)
BR (1) BR0208685A (de)
CA (3) CA2827167A1 (de)
CY (1) CY1108817T1 (de)
DE (1) DE60230029D1 (de)
DK (3) DK2006301T3 (de)
EE (2) EE200300487A (de)
ES (2) ES2546293T3 (de)
IL (4) IL158285A0 (de)
PL (4) PL217858B1 (de)
PT (1) PT1383526E (de)
RU (1) RU2296582C2 (de)
SE (1) SE0103754L (de)
WO (1) WO2002080954A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
BR0212880A (pt) 2001-09-28 2005-12-13 Esperion Therapeutics Inc Uso de uma droga moduladora de lipìdeo, kit para tratamento ou redução, stent revestido com um material a ser liberado em um local a ser tratado, e composição farmacêutica
CA2500895A1 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302422D0 (sv) 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
SE0400683D0 (sv) 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
EP1732383A4 (de) 2004-04-06 2007-05-02 Cedars Sinai Medical Center Vorbeugung und behandlung von gefässerkrankungen mit rekombinanten adeno assoziierten virusvektoren, die für apolipoprotein a-i und apolipoprotein a-i milano kodieren
ES2357606T3 (es) * 2004-04-15 2011-04-28 Athera Biotechnologies Ab Anticuerpos contra conjugados de fosforilcolina.
EP1676602A1 (de) 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Kontinuierlicheverabreichung von Epitope aus dem atherosklerotischem Belag zur Behandlung von Atheriosklerose
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
EP2115466A4 (de) * 2006-12-22 2010-07-28 Abbott Lab Herz-kreislauf-autoimmunkrankheit-testgruppe und verfahren zur verwendung davon
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
CN101657430B (zh) 2007-03-15 2013-05-01 诺瓦提斯公司 有机化合物及其用途
US9359633B2 (en) * 2007-11-05 2016-06-07 Nordic Bioscience A/S Biochemical markers for CVD risk assessment
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CN102099470B (zh) * 2008-08-15 2014-11-12 藤仓化成株式会社 用于诊断动脉硬化的多肽标记、用该标记等检测动脉硬化的方法以及用于诊断动脉硬化的试剂盒
CN102939536A (zh) * 2009-11-14 2013-02-20 匡-宇·邱 用于治疗和/或预防动脉粥样硬化的免疫调节方法和***
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
RU2013126888A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер ИММУНОМОДУЛИРУЮЩИЕ КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ, СОДЕРЖАЩИЕ ИММУНОГЕННЫЕ ФРАГМЕНТЫ АроВ100
CA2817538A1 (en) 2010-11-12 2012-05-18 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
AU2011336997A1 (en) 2010-11-12 2013-05-30 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
MX364425B (es) 2011-08-09 2019-04-25 Athera Biotechnologies Ab Star Nuevos anticuerpos contra fosforilcolina.
CN103906532B (zh) 2011-08-09 2018-01-26 阿瑟拉生物技术公司 结合磷酰胆碱（pc）和/或pc结合物的抗体
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
CA2888657C (en) 2012-11-06 2022-05-03 Les Hopitaux Universitaires De Geneve Mimetic peptides
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN103860470A (zh) * 2014-03-05 2014-06-18 贵州中泰生物科技有限公司 一种口服高密度脂蛋白脂质体的制备方法
CN105315364B (zh) * 2014-06-17 2018-09-18 广州文瑞生物科技有限公司 胶原蛋白vi疫苗预防动脉粥样硬化
WO2016187250A1 (en) * 2015-05-19 2016-11-24 La Jolla Institute For Allergy And Immunology Human apob100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN108478817B (zh) * 2018-03-16 2020-10-27 北京大学 一种动脉粥样硬化检测试剂及其制备方法
US11690912B2 (en) 2018-05-29 2023-07-04 Abcentra, Llc Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
EP3801590A4 (de) 2018-05-29 2022-03-16 Abcentra, LLC Zusammensetzungen und verfahren zur behandlung von schuppenflechte

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
WO1993018067A1 (en) * 1992-03-06 1993-09-16 Abbott Laboratories Immunocapture assay for direct quantitation of specific lipoprotein cholesterol levels
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
KR0185334B1 (ko) 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6156315A (en) * 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
US6309844B1 (en) * 1997-10-15 2001-10-30 Fujirebio Inc. Anti-apo-B-48 monoclonal antibody, hybridoma producing the same, and method for measuring apo-B-48 using the same
EP1062512A4 (de) * 1998-03-10 2001-12-12 Univ California Verfahren und hilfsmittel zum identifizieren von verbindungen, die atherosklerose modulieren indem sie ldl-proteoglykanbindungen beeinflussen
WO2000002920A1 (en) * 1998-07-13 2000-01-20 University Of Otago Inhibition of lipoprotein formation
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
WO2001032070A2 (en) * 1999-10-26 2001-05-10 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
AU3087801A (en) * 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
ATE265860T1 (de) * 2000-03-03 2004-05-15 Glaxosmithkline Biolog Sa Impstoff zur behandlung von atherosclerosis
SE0000855D0 (sv) * 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
EP1186299A1 (de) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems
AU2002243382A1 (en) * 2000-10-25 2002-06-24 Vincent Agnello Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
WO2002042426A2 (en) * 2000-11-10 2002-05-30 University Of Utah Research Foundation Carrier system for specific artery wall gene delivery
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
BR0209572A (pt) * 2001-05-15 2004-07-13 Japan Immunores Lab Co Ltd Peptìdeo reativo com lipoproteìna de alta densidade
CA2454418A1 (en) * 2001-07-20 2003-01-30 Eidgenoessische Technische Hochschule Zurich (Ethz) Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids

Also Published As

Publication number Publication date
CN1505525B (zh) 2012-11-07
JP5300820B2 (ja) 2013-09-25
CN103122031A (zh) 2013-05-29
EP2295464B1 (de) 2015-06-03
EP2295463A1 (de) 2011-03-16
EP2289924A1 (de) 2011-03-02
EP2289914A1 (de) 2011-03-02
CN101486766A (zh) 2009-07-22
EP2289927A1 (de) 2011-03-02
CN101284874B (zh) 2012-10-03
CA2606839A1 (en) 2002-10-17
EP2289922A1 (de) 2011-03-02
EP2289934A1 (de) 2011-03-02
EE200300487A (et) 2004-02-16
EP2289926A1 (de) 2011-03-02
JP2009191078A (ja) 2009-08-27
JP2013144687A (ja) 2013-07-25
AU2002246484B2 (en) 2007-04-19
JP5270456B2 (ja) 2013-08-21
EP2289921A1 (de) 2011-03-02
EP2289923A1 (de) 2011-03-02
JP2011068654A (ja) 2011-04-07
BR0208685A (pt) 2004-03-30
EP2289932A1 (de) 2011-03-02
CN103122031B (zh) 2015-07-22
EP2147680A3 (de) 2010-04-14
CY1108817T1 (el) 2014-04-09
EP2289916A1 (de) 2011-03-02
EP2289933A1 (de) 2011-03-02
EP2289912A1 (de) 2011-03-02
EP2289913A1 (de) 2011-03-02
EP2289918A1 (de) 2011-03-02
EP2289915A1 (de) 2011-03-02
EP2289917A1 (de) 2011-03-02
EP2147930A2 (de) 2010-01-27
ES2317999T3 (es) 2009-05-01
PL400308A1 (pl) 2012-12-17
EP2295457A1 (de) 2011-03-16
AU2002246484A1 (en) 2002-10-21
SE0103754L (sv) 2002-10-06
PL215401B1 (pl) 2013-12-31
EP2289935A1 (de) 2011-03-02
RU2296582C2 (ru) 2007-04-10
EP1383526A1 (de) 2004-01-28
EP2289934B1 (de) 2013-11-13
IL158285A0 (en) 2004-05-12
IL188286A0 (en) 2008-03-20
EP2147929A2 (de) 2010-01-27
JP5613890B2 (ja) 2014-10-29
CA2827167A1 (en) 2002-10-17
EE200700052A (et) 2008-08-15
EP2289929A1 (de) 2011-03-02
DK2295464T3 (en) 2015-08-17
CA2606839C (en) 2015-06-09
DK2006301T3 (da) 2011-09-12
CN101284874A (zh) 2008-10-15
EP2147928A3 (de) 2010-04-14
AU2002246484B8 (en) 2007-06-14
EP2305706A1 (de) 2011-04-06
CN1505525A (zh) 2004-06-16
EP2147929A3 (de) 2010-04-14
ATE415423T1 (de) 2008-12-15
SE0103754D0 (sv) 2001-11-09
EP1918300A3 (de) 2009-06-17
DK1383526T3 (da) 2009-03-30
EP2295460B1 (de) 2015-06-03
IL195356A0 (en) 2009-08-03
EP2147680A2 (de) 2010-01-27
PT1383526E (pt) 2009-02-27
EP2289928A1 (de) 2011-03-02
WO2002080954A1 (en) 2002-10-17
JP2008169215A (ja) 2008-07-24
EP1918300A2 (de) 2008-05-07
EP2289930A1 (de) 2011-03-02
EP2305708A1 (de) 2011-04-06
EP2289920A1 (de) 2011-03-02
EP2147928A2 (de) 2010-01-27
IL158285A (en) 2009-12-24
CA2443223A1 (en) 2002-10-17
EP2295461A1 (de) 2011-03-16
EP1383526B1 (de) 2008-11-26
PL217858B1 (pl) 2014-08-29
ATE510851T1 (de) 2011-06-15
EP2295464A1 (de) 2011-03-16
EP2147930A3 (de) 2010-04-14
EP2295458A1 (de) 2011-03-16
ES2546293T3 (es) 2015-09-22
EP2289931A1 (de) 2011-03-02
CA2443223C (en) 2013-11-26
EP2295462A1 (de) 2011-03-16
EP2289925A1 (de) 2011-03-02
RU2003132443A (ru) 2005-02-27
EP2289919A1 (de) 2011-03-02
JP2004529143A (ja) 2004-09-24
JP2011063598A (ja) 2011-03-31
EP2006301A1 (de) 2008-12-24
PL367301A1 (en) 2005-02-21
EP2295459A1 (de) 2011-03-16
EP2006301B1 (de) 2011-05-25
EP2305707A1 (de) 2011-04-06
EP2295460A1 (de) 2011-03-16
JP5300819B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
ATE415423T1 (de) Immunisierungstherapie zur behandlung von atherosklerose
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
AT500379B8 (de) Tau-proteine
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
ATE470676T1 (de) Anti-vegf-2 antikörper
HK1088909A1 (en) Peptide-based immunization therapy for treatment of atherosclerosis
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
ATE329898T1 (de) Kombinationspräparat zur therapie von immunologischen erkrankungen
BRPI0216049B8 (pt) "terapia de imunização à base de peptídeo para tratamento de arteriosclerose"

Legal Events

Date Code Title Description
8364 No opposition during term of opposition